See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: July 2, 2007

Alzheimer Disease Rheumatoid Arthritis Nocturia

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Alzheimer Disease

This study will evaluate an investigational drug for Alzheimer's disease. Participants will receive study supervision by a board-certified neurologist, study related tests and exams, and the investigational drug at no cost. Compensation is available for time and travel.

The research site is in Phoenix, Ariz.

More information

Please see http://www.centerwatch.com/patient/studies/cat11.html.

-----

Rheumatoid Arthritis

This study will evaluate the effectiveness of an investigational medication, taken in addition to methotrexate, to control the signs and symptoms of rheumatoid arthritis. Participants must be at least 18, have active rheumatoid arthritis, be taking 10 mg. to 25 mg. of methotrexate per week, and have at least six tender joints and at least six swollen joints.

The research site is in New Port Richey, Fla.

More information

Please see http://www.centerwatch.com/patient/studies/cat132.html.

-----

Nocturia

This study will test the safety and effectiveness of a fast-dissolving formulation of an investigational medication for nocturia. Participants must be 18 or older, and average two or more nightly trips to the bathroom to urinate. Patients must not take diuretics or water pills, and cannot have diabetes or uncontrolled high blood pressure.

The research site is in Tarzana, Calif.

More information

Please see http://www.centerwatch.com/patient/studies/cat592.html.

-----

Copyright 2007 Thomson CenterWatch. All rights reserved.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.